Drug intelligence / Profile preview

TT301

Development stage: Unknown
Lead developer: Tempo Therapeutics
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

TT301 is a precision-engineered microporous annealed particle (MAP) hydrogel scaffold developed by Tempo Therapeutics for tissue regeneration and the treatment of complex wounds. The technology utilizes monodisperse microgel beads that are annealed in situ to form an interconnected pore network, which facilitates immediate cellular infiltration and rapid vascularization. TT301 is designed to modulate the wound microenvironment by promoting a pro-regenerative immune response, specifically shifting the local macrophage population toward an M2 phenotype. This mechanism aims to accelerate healing and reduce scarring in complex surgical wounds and other full-thickness skin injuries.

Other names: MAP hydrogel scaffold

Beyond the preview

Go deeper on TT301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT301.

Explore the full profile